TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31018221

Group type: COMPARATOR
Intervention: Predictive learning model
Number of subjects: 102
Study: 28000180

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (5-10 g gel/50-100 mg testosterone)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (5-10 g gel)
Number of subjects: 48
Study: 25583994

Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 5749
Study: 24858152

Group type: EXPERIMENTAL
Intervention: Long regimen: prednisolone 60mg/m²/day for six weeks followed by 40mg/m² every alternate day for six weeks.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard regimen: prednisolone 60mg/m²/day for four weeks followed by 40mg/m² every alternate day for four weeks.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups (long and standard regimen)
Number of subjects: 93
Study: 22947258

Group type: EXPERIMENTAL
Intervention: High-relevance conducive conditions
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Conducive conditions
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Relevance conditions
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Feeling self-report
Number of subjects: 119
Study: 19426995

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17602078

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy in patients with p27Kip1-negative tumors
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy in patients with p27Kip1-positive tumors
Number of subjects: 778

Group type: COMPARATOR
Intervention: Control group (no cisplatin-based chemotherapy)
Number of subjects: 778
Study: 14988890

Group type: EXPERIMENTAL
Intervention: X‐Press device
Number of subjects: 393
Study: 11223497

Group type: EXPERIMENTAL
Intervention: OM‐85 BV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9420397

Group type: EXPERIMENTAL
Intervention: Therapy for malignancies
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal controls (healthy adults)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Negative skin test and T‐cell population less than 40%
Number of subjects: 28
Study: 8213706

Group type: EXPERIMENTAL
Intervention: 10 mg po metoclopramide (single dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg po quid for 7 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3628545

Group type: EXPERIMENTAL
Intervention: High fat diet (40% energy from fat)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low fat diet (20% energy from fat)
Number of subjects: 30
Study: 31564177

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 500

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 500
Study: 29404806

Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day; 3 weeks on/1 week off) plus Letrozole (2.5 mg/day; continuous)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo plus Letrozole
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Ribociclib plus Letrozole
Number of subjects: 668
Study: 28762932

Group type: EXPERIMENTAL
Intervention: Multivessel stenting using 2nd generation drug covered stents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staged revascularization using 2nd generation drug covered stents
Number of subjects: 0
Study: 25612788

Group type: EXPERIMENTAL
Intervention: Monetary incentive of $300 offered to participate (incentive group)
Number of subjects: 1314

Group type: COMPARATOR
Intervention: No monetary incentive offered (no-incentive group)
Number of subjects: 1314
Study: 22027932

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1% (Voltaren Ophthalmic)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Topical dexamethasone sodium phosphate 0.1% (Sterodex)
Number of subjects: 42
Study: 20097101

Group type: EXPERIMENTAL
Intervention: Dentoalveolar distraction osteogenesis
Number of subjects: 12
Study: 18996856

Group type: EXPERIMENTAL
Intervention: Accumulated brisk walking (ten 3-min bouts)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Continuous brisk walking (one 30-min bout)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 15
Study: 17011412

Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lempert maneuver
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients with H‐BPPV
Number of subjects: 0
Study: 14616980

Group type: EXPERIMENTAL
Intervention: Vitamin E (525 IU daily for 3 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 25
Study: 11040224

Group type: EXPERIMENTAL
Intervention: Elastic modulus (pressure-dependent method)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Systolic and diastolic pressures
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Beta (pressure-independent stiffness index)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Arterial compliance index
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Beta (younger vs older hypertensives)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Elastic modulus (younger vs older hypertensives)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Arterial compliance index (younger vs older hypertensives)
Number of subjects: 276
Study: 9582466

Group type: EXPERIMENTAL
Intervention: 5‐FU/adrenaline gel
Number of subjects: 319

Group type: COMPARATOR
Intervention: 5‐FU/adrenaline solution
Number of subjects: 319

Group type: COMPARATOR
Intervention: 5‐FU gel
Number of subjects: 319
Study: 8345231

Group type: EXPERIMENTAL
Intervention: Modified multidrug therapy regimen (rifampicin 600 mg, clofazimine 100 mg, dapsone 100 mg daily for 21 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard WHO multidrug regimen (rifampicin 600 mg and clofazimine 300 mg monthly, dapsone 100 mg daily, clofazimine 100 mg on alternate days)
Number of subjects: 30
Study: 3578865

Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5%/15 mg with 0.2 mg epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%/20 mg without epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 31504526

Group type: EXPERIMENTAL
Intervention: High Dose (HD) Influenza Vaccine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard Dose (SD) Influenza Vaccine
Number of subjects: 69
Study: 28237072

Group type: EXPERIMENTAL
Intervention: Ballena orthotic
Number of subjects: 84

Group type: COMPARATOR
Intervention: Colditz orthotic
Number of subjects: 84
Study: 26822388

Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TENS plus tongue trills
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (15 subjects from EG1 and 15 subjects from EG2)
Number of subjects: 60
Study: 25491621

Group type: EXPERIMENTAL
Intervention: Selective retention of the great saphenous vein trunk below the knee
Number of subjects: 280

Group type: COMPARATOR
Intervention: Stripping the great saphenous vein to the ankle level (Control)
Number of subjects: 280
Study: 22737871

Group type: EXPERIMENTAL
Intervention: Combined therapy group (intratyimpanic dexamethasone and basic drug group treatment)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Basic drug group (ganglioside and vinpocetine injection)
Number of subjects: 90
Study: 19437180

Group type: EXPERIMENTAL
Intervention: Dietary modification program
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Physical activity skill development program
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Combination of both programs
Number of subjects: 159
Study: 18787328

Group type: EXPERIMENTAL
Intervention: Qigong intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study: 15790946

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate therapy (64 mmol/L per day, continuous intravenous dose, started within 4 days after SAH and continued until 14 days after occlusion of the aneurysm)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate therapy
Number of subjects: 283
Study: 11451715

Group type: EXPERIMENTAL
Intervention: Reduced-fat spread enriched with plant sterol esters (1.1 g/d)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Reduced-fat spread enriched with plant sterol esters (2.2 g/d)
Number of subjects: 224
Study: 9735936

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200000 IU for infants > 6 months, 400000 IU for children 1-4 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8297739

Group type: EXPERIMENTAL
Intervention: CEF + GM-CSF (10 micrograms kg-1 s.c. starting from day 4)
Number of subjects: 62

Group type: COMPARATOR
Intervention: CEF (cyclophosphamide 600 mg m-2, epidoxorubicin 60 mg m-2 and fluorouracil 600 mg m-2)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CEF + GM-CSF
Number of subjects: 62
Study: 2646253

Group type: EXPERIMENTAL
Intervention: Pre-operative radiation combined with surgery (4,000 cGy delivered to the whole mediastinum and left gastroepiploic lymphatic chain)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Patients with lesions showing radiation reaction of grade III
Number of subjects: 206
Study: 7975663

Group type: EXPERIMENTAL
Intervention: L-arginine infusion at a dose of 12.63g in 300 ml of 0.9% NaCl over 90 min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 4
Study: 378671

Group type: EXPERIMENTAL
Intervention: Once daily Sotalol (80 to 320mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Twice daily Sotalol (80 to 320mg/day)
Number of subjects: 30
Study: 30228034

Group type: EXPERIMENTAL
Intervention: 1.02‐mm‐sized TTs (thermoplastic elastomer)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 1.14‐mm‐sized TTs (silicone)
Number of subjects: 75
Study: 28039187

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with ambrisentan and tadalafil
Number of subjects: 500
Study: 26028098

Group type: EXPERIMENTAL
Intervention: 7-day levofloxacin-dexlansoprazole based quadruple therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 14-day levofloxacin-dexlansoprazole based quadruple therapy
Number of subjects: 100
Study: 24382103

Group type: EXPERIMENTAL
Intervention: Dietary Effects on Lipids and Thrombogenic Activity (DELTA) Study
Number of subjects: 103
Study: 21955635

Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (1.25 mg/0.1 mL) injected immediately after surgical excision of the pterygium
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo administered in the same way
Number of subjects: 80
Study: 18692827

Group type: EXPERIMENTAL
Intervention: Fluorescent in situ hybridization (FISH) for chromosomes X, Y, 13, 15, 16, 17, 18, 21, and 22
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no preimplantation aneuploidy testing)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Test group (preimplantation aneuploidy testing)
Number of subjects: 62
Study: 17493446

Group type: EXPERIMENTAL
Intervention: Intensive control of cardiovascular risk factors (CVRF) protocol
Number of subjects: 184

Group type: COMPARATOR
Intervention: Normal practice (control group)
Number of subjects: 184
Study: 14760477

Group type: EXPERIMENTAL
Intervention: AneuRx device
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Zenith device
Number of subjects: 41
Study: 11427642

Group type: EXPERIMENTAL
Intervention: Lisinopril (LIS, n=35)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF, n=40)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (normotensive recipients, n=10)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lisinopril (LIS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (normotensive recipients)
Number of subjects: 75
Study: 9728834

Group type: EXPERIMENTAL
Intervention: Epidural lidocaine plus epidural fentanyl
Number of subjects: 14

Group type: COMPARATOR
Intervention: Epidural lidocaine alone
Number of subjects: 14
Study: 7750682

Group type: EXPERIMENTAL
Intervention: Ranitidine (600 mg/day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg/day)
Number of subjects: 75
Study: 3386845

Group type: EXPERIMENTAL
Intervention: Copolymer 1 (COP-1) - daily intramuscular doses of 20 mg (2 patients) and twice daily subcutaneous doses of 15 mg (3 patients)
Number of subjects: 5
Study: 31857264

Group type: COMPARATOR
Intervention: ICD-9-CM codes alone
Number of subjects: 3907

Group type: EXPERIMENTAL
Intervention: NLP in combination with ICD-9-CM codes
Number of subjects: 3907

Group type: EXPERIMENTAL
Intervention: NLP
Number of subjects: 3907
Study: 31512258

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ofatumumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibrutinib in genomic high-risk population
Number of subjects: 0
Study: 28684258

Group type: EXPERIMENTAL
Intervention: Real anodal tDCS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study: 26557471

Group type: EXPERIMENTAL
Intervention: 9-session in-person culturally-based ¡Cocinar para su salud! dietary modification program
Number of subjects: 102

Group type: COMPARATOR
Intervention: Written materials (control arm)
Number of subjects: 102
Study: 24010917

Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control meningococcal (ACYW135) conjugate vaccine
Number of subjects: 206
Study: 21534244

Group type: EXPERIMENTAL
Intervention: HD+HP (hemodialysis with hemoperfusion) once a week
Number of subjects: 100

Group type: COMPARATOR
Intervention: HD (hemodialysis) alone 3 times a week
Number of subjects: 100
Study: 19798013

Group type: EXPERIMENTAL
Intervention: Posterior psoas compartment approach (N=18) using 30 mL of 1.5% mepivacaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Anterior 3‐in‐1 femoral nerve block (N=18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Posterior psoas compartment approach
Number of subjects: 36

Group type: COMPARATOR
Intervention: Anterior 3‐in‐1 femoral nerve block
Number of subjects: 36
Study: 16548084

Group type: EXPERIMENTAL
Intervention: NMES therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 12923651

Group type: EXPERIMENTAL
Intervention: Tomato products (raw, sauce, and paste) providing approximately eight mg lycopene/day for three weeks (T21)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carotenoid-poor diet (T0)
Number of subjects: 12
Study: 11232753

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg/day)
Number of subjects: 1658
Study: 9931882

Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant intraoperative radiotherapy (IORT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 7799586

Group type: EXPERIMENTAL
Intervention: Intravascular quantum hemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined methods of quantum hemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2623032

Group type: EXPERIMENTAL
Intervention: 10 mg oral d-amphetamine in fasting state (FAST/DRUG)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg oral d-amphetamine in fed state (FED/DRUG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo in fasting state (FAST/PLACEBO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo in fed state (FED/PLACEBO)
Number of subjects: 12
Study: 31769371

Group type: EXPERIMENTAL
Intervention: Prevalent high PTSD symptoms
Number of subjects: 51965

Group type: EXPERIMENTAL
Intervention: New-onset high PTSD symptoms
Number of subjects: 51965

Group type: COMPARATOR
Intervention: No trauma exposure
Number of subjects: 51965
Study: 31056427

Group type: EXPERIMENTAL
Intervention: Low-dose CAL02 (4 mg/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-dose CAL02 (16 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined CAL02 groups
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 28205117

Group type: EXPERIMENTAL
Intervention: Costoclavicular ultrasound-guided infraclavicular block
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paracoracoid ultrasound-guided infraclavicular block
Number of subjects: 90
Study: 25840550

Group type: EXPERIMENTAL
Intervention: Leukocyte telomere length (LTL)
Number of subjects: 353
Study: 24005546

Group type: EXPERIMENTAL
Intervention: Indirect alcohol use biomarkers (GGT, AST)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GGT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Direct alcohol use biomarkers
Number of subjects: 30
Study: 21393255

Group type: EXPERIMENTAL
Intervention: L-BLP25 liposome vaccine (1000 μg subcutaneously)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (300 mg/m2 i.v. single dose)
Number of subjects: 6
Study: 19624964

Group type: COMPARATOR
Intervention: Passive strategy (Group I)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Participative educative strategy (Group II)
Number of subjects: 22
Study: 18026868

Group type: EXPERIMENTAL
Intervention: Cod-based diet
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Seafood-based diets
Number of subjects: 276

Group type: COMPARATOR
Intervention: Fish-restricted diet (control)
Number of subjects: 276
Study: 15539013

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11558044

Group type: EXPERIMENTAL
Intervention: Lumbar extension exercise (MedX)
Number of subjects: 1100
Study: 9432196

Group type: EXPERIMENTAL
Intervention: Made-to-order polysomnograms (single-night sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional polysomnograms (double-night sessions)
Number of subjects: 80
Study: 8418246

Group type: EXPERIMENTAL
Intervention: Intravenous diaziquone (AZQ)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Carmustine (BCNU)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: AZQ with significant hematologic toxicity requiring dose reduction
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Older age (45+) and glioblastoma/gliosarcoma (GBM/GS)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Older age or GBM/GS
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Younger age (< 45) and non-GBM/GS (usually anaplastic astrocytoma)
Number of subjects: 251

Group type: COMPARATOR
Intervention: BCNU
Number of subjects: 251
Study: 3530138

Group type: EXPERIMENTAL
Intervention: MCOP (mitoxantrone, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 44

Group type: COMPARATOR
Intervention: CHOP (adriamycin, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MCOP
Number of subjects: 44

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MCOP and CHOP
Number of subjects: 44
Study: 29131689

Group type: EXPERIMENTAL
Intervention: Pedometer use
Number of subjects: 27
Study: 26519751

Group type: EXPERIMENTAL
Intervention: Segmental mirroring (Group II)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mirroring of the entire unaffected side (Group I)
Number of subjects: 50
Study: 25069621

Group type: EXPERIMENTAL
Intervention: Technology-based intervention (empirically supported behavior-change strategies, daily skills, self-monitoring text messages with personalized feedback, biweekly counseling calls from a health coach, access to a Facebook support group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Technology-based intervention
Number of subjects: 18
Study: 22692758

Group type: EXPERIMENTAL
Intervention: MVA-5T4 (TroVax)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20210368

Group type: EXPERIMENTAL
Intervention: Rituximab (as a single agent or in combination with chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab added to CHOP chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy followed by autologous haematopoietic cell transplant (autoHCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AutoHCT in highly selected individuals up to age 70 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Close observation until specific therapeutic indications arise
Number of subjects: 0
Study: 18601670

Group type: EXPERIMENTAL
Intervention: Bifocal soft contact lenses (BSCL)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Single vision soft contact lenses (SVSCL)
Number of subjects: 2
Study: 15980707

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 39

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 39
Study: 12452245

Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg before skin incision
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg after skin incision
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg and ketamine 30 mg before skin incision
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg and ketamine 30 mg after skin incision
Number of subjects: 80
Study: 10604407

Group type: EXPERIMENTAL
Intervention: Beta-carotene 60 mg/d for 6 months, followed by randomization to continue beta-carotene or placebo for 12 additional months.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo after initial beta-carotene treatment.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Beta-carotene treatment for 6 months.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo after beta-carotene treatment.
Number of subjects: 50
Study: 7864103

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) administration (12.5-24 micrograms.kg-1.day-1; n = 8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 23